Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01332227
Other study ID # AI424-402
Secondary ID 2009-017032-41
Status Completed
Phase Phase 4
First received April 7, 2011
Last updated February 2, 2015
Start date October 2011
Est. completion date February 2014

Study information

Verified date February 2015
Source Bristol-Myers Squibb
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationGermany: Federal Institute for Drugs and Medical DevicesFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Spain: Ministry of HealthItaly: The Italian Medicines AgencyPoland: Ministry of HealthUnited Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether HIV-1—infected patients, who are virologically suppressed on a regimen of 2 nucleoside reverse transcriptase inhibitors plus any third agent but are experiencing safety and/or tolerability issues, will maintain virologic suppression after switching to a regimen of heat-stable ritonavir boosted atazanavir, 300/100 mg, once daily plus raltegravir, 400 mg, twice daily.


Description:

Allocation: Randomized nonstratified

Intervention model: Parallel versus comparator


Recruitment information / eligibility

Status Completed
Enrollment 132
Est. completion date February 2014
Est. primary completion date September 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Key Inclusion Criteria

- Current treatment regimen of 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus any third agent for at least 3 months immediately prior to screening

- Virologic suppression (HIV-1 RNA <50 c/mL) for at least 3 months immediately prior to screening

- Virologic suppression (HIV-1 RNA <40 c/mL) using the Abbott m2000rt® polymerase chain reaction assay during screening period

- Treatment-related safety and/or tolerability issues to a regimen consisting of 2 NRTIs plus any third agent

Key Exclusion Criteria

- History of switch in highly active antiretroviral therapy due to virologic failure

- History of genotypic resistance to any component of the study regimen (atazanavir, raltegravir, tenofovir/emtricitabine)

- History of exposure to atazanavir/ritonavir or raltegravir prior to entering the study

- Experiencing safety and/or tolerability issues to tenofovir/emtricitabine or raltegravir

- Switch of any component of HIV antiretroviral medication regimen in the last 3 months immediately prior to or during the screening period

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Atazanavir
Capsules, Oral, 300mg, Once daily, 48 weeks
Ritonavir (heat-stable)
Tablets, Oral, 100 mg, Once daily, 48 weeks
Raltegravir
Tablets, Oral, 400 mg, Twice daily, 48 weeks
Tenofovir/Emtricitabine
Tablets, Oral, 300/200 mg, Once daily, 48 weeks

Locations

Country Name City State
France Local Institution Lyons Cedex 04
France Local Institution Orleans Cedex 2
France Local Institution Paris
France Local Institution Paris Cedex 12
France Local Institution Paris Cedex 14
France Local Institution Strasbourg Cedex
Germany Local Institution Bochum
Germany Local Institution Frankfurt
Germany Local Institution Frankfurt Am Main
Germany Local Institution Hamburg
Germany Local Institution Munich
Italy Local Institution Genova
Italy Local Institution Genova
Italy Local Institution Milano
Italy Local Institution Milano
Italy Local Institution Roma
Poland Local Institution Warszawa
Poland Local Institution Wroclaw
Spain Local Institution Alicante
Spain Local Institution Barcelona
Spain Local Institution Madrid
Spain Local Institution Madrid
Spain Local Institution Madrid
Spain Local Institution Madrid
United Kingdom Local Institution Brighton
United Kingdom Local Institution London
United Kingdom Local Institution London
United Kingdom Local Institution London Greater London
United Kingdom Local Institution Manchester Greater Manchester
United Kingdom Local Institution Sheffield
United States Consultive Medicine Daytona Beach Florida
United States Health For Life Clinic Pllc Little Rock Arkansas
United States Orange County Health Dept. Orlando Florida
United States Eisenhower Medical Center Palm Springs California
United States Aids Care Rochester New York
United States Metropolis Medical Pc San Francisco California
United States The Research Institute Springfield Massachusetts
United States Triple O Medical Services, P.A. West Palm Beach Florida

Sponsors (1)

Lead Sponsor Collaborator
Bristol-Myers Squibb

Countries where clinical trial is conducted

United States,  France,  Germany,  Italy,  Poland,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants With HIV-1 RNA Level <40 c/mL at Week 24 HIV-1 RNA level was measured with the Abbott m2000rt® polymerase chain reaction assay. Response rates were assessed using an intent-to-treat algorithm, with numerator representing patients meeting the response criteria, and denominator representing all randomized patients. Randomized patients not meeting the criteria for treatment failure (eg, discontinuation of study therapy or virologic rebound at or before Week 24) were considered responders. Virologic rebound was defined as 2 consecutive on-treatment HIV-1 RNA levels =40 c/mL or the last on-treatment HIV-1 RNA level =40 c/mL followed by discontinuation. Patients who experienced treatment failure or had missing Week 24 HIV-1 RNA levels were considered failures. RNA=ribonucleic acid; HIV=human immunodeficiency virus. From Day 1 to Week 24 No
Secondary Percentage of Participants With HIV-1 RNA Level <40 c/mL at Week 48 Percentages of patients with HIV-1 RNA levels <40 c/mL were summarized at each scheduled visit. Longitudinal plots were created to display proportion versus visit week through Weeks 24 and 48 with error bars representing 95% confidence intervals. From Day 1 to Week 48 No
Secondary Number of Participants With Virologic Rebound at Weeks 24 and 48 Viral genotypic and phenotypic resistance profiles were assessed for virologic rebound (HIV-1 RNA level =40 c/mL). Only patients with HIV-1 RNA levels =500 c/mL met the criteria for resistance testing. Genotypic substitutions at baseline were summarized for virologic rebound. The genotypic resistance profile presented patients with genotypable isolates, those with protease inhibitor substitutions from genotypable isolates, those with integrase substitutions from genotypable isolates, and those with selected reverse transcriptase substitutions from genotypable isolates using the most current version of the International AIDS Society-USA list and Stanford HIV Drug Resistance Database. Newly emergent genotypic substitutions were summarized analogously for virologic rebound without baseline phenotypic resistance to atazanavir, ritonavir, or raltegravir, using all on-treatment isolates. Day 1 to Weeks 28 and 48 No
Secondary Number of Participants With Genotypable/Phenotypable Isolates, Emergent Genotypic Substitutions in Patients With Genotypable Isolates, and Phenotypic Resistance in Patients With Phenotypable Isolates at Week 24 Viral genotypic and phenotypic resistance profiles were assessed for virologic rebound (HIV-1 RNA level =40 c/mL). Only patients with HIV-1 RNA levels =500 c/mL met the criteria for resistance testing. Genotypic substitutions at baseline were summarized for virologic rebound. The genotypic resistance profile presented patients with genotypable isolates, those with protease inhibitor substitutions from genotypable isolates, those with integrase substitutions from genotypable isolates, and those with selected reverse transcriptase substitutions from genotypable isolates using the most current version of the International AIDS Society-USA list and Stanford HIV Drug Resistance Database. Newly emergent genotypic substitutions were summarized analogously for virologic rebound without baseline phenotypic resistance to atazanavir, ritonavir, or raltegravir, using all on-treatment isolates. pts=patients Day 1 to Week 24 No
Secondary Number of Participants With Genotypable/Phenotypable Isolates, Emergent Genotypic Substitutions in Patients With Genotypable Isolates, and Phenotypic Resistance in Patients With Phenotypable Isolates at Week 48 Viral genotypic and phenotypic resistance profiles were assessed for virologic rebound (HIV-1 RNA level =40 c/mL). Only patients with HIV-1 RNA levels =500 c/mL met the criteria for resistance testing. Genotypic substitutions at baseline were summarized for virologic rebound. The genotypic resistance profile presented patients with genotypable isolates, those with protease inhibitor substitutions from genotypable isolates, those with integrase substitutions from genotypable isolates, and those with selected reverse transcriptase substitutions from genotypable isolates using the most current version of the International AIDS Society-USA list and Stanford HIV Drug Resistance Database. Newly emergent genotypic substitutions were summarized analogously for virologic rebound without baseline phenotypic resistance to atazanavir, ritonavir, or raltegravir, using all on-treatment isolates. pts=patients Day 1 to Week 48 No
Secondary Number of Patients With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, Treatment-emergent Adverse Events (AEs) Leading to Discontinuation, and Treatment-emergent AEs AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Related=having certain, probable, possible, or unknown relationship to study drug. Day 1 to Week 48 Yes
Secondary Mean Changes in Fasting Lipid Levels From Baseline to Week 48 LD=low-density lipoprotein; HDL=high-density lipoprotein. From Baseline to Week 48 Yes